IL-STATS
25.7.2017 09:32:10 CEST | Business Wire | Press release
STATS, the global leader in sports data and intelligence, has launched an innovative new product, STATS Edge. STATS Edge is a search and analytics application powered by artificial intelligence that enables football teams to instantly find video clips and analyse complex patterns in a game with more speed and accuracy than ever before. With the power of AI-driven analytics at their fingertips, analysts can instantly and effectively assess in detail a team’s strengths and weaknesses while focusing on various aspects of the game.
Drawing on STATS’ rich history in data collection and analysis, STATS Edge will utilise data from the Premier League, Championship, La Liga, Ligue de Football Professionnel, Serie A, Bundesliga, Qatar Stars League, Champions League and more. STATS Edge will initially be available in five languages.
STATS Edge unifies football data and video through an easy-to-use and intuitive user interface, developed in close partnership with top English, French and Spanish clubs through a design-thinking methodology. This allows everyone in the football club – from match analysts to the manager – to analyse, annotate and share insights on the same platform.
“It’s increasingly difficult for clubs to process and analyse all the relevant data points available and distil complex information into timely, accurate insight,” said Kenneth Fuchs, STATS’ CEO. “On top of that, traditional analytics don’t always speak the visual language of players and coaches. We’ve applied computer vision and artificial intelligence to bring new levels of context and efficiency to teams already using video for their match preparations. It’ll save them time, allow them to develop proprietary results, and help get them the information to make, share and track the best decisions.”
The STATS Edge search engine allows managers and analysts to use their football vocabulary within a search box to find relevant video clips in seconds across entire leagues or competitions, regardless of the complexity of their queries. They can link a multitude of events and playing styles to search, which allows the execution of more than 1,000 search combinations.
The ability to search across players, teams, styles, set plays and more using natural language is a substantial step forward in accessing complex tracking data in a simple interface. For example, STATS Edge lets users quickly find and retrieve all of a team’s counter attacks which led to goals, a player’s key events such as shots or crosses in the last five games, or passes into a custom defined zone on the pitch. This use of analytics also helps clubs assess the value of a transfer target in order to reach a fully informed decision before making an investment.
Once clips are identified, STATS’ proprietary Exemplar Search, built by its award-winning data science team, can instantly find clips of similar plays at the click of a button. By using AI algorithms, the platform reads the combination of player and ball trajectories as well as events in any clip to retrieve the respective Exemplar Search results.
STATS Edge further builds on the power of AI to provide exciting and intuitive analytical features, starting with set plays and transitions. By dynamically specifying a zone on the field and other variables, the manager and analyst instantly accesses in-depth analysis and all corresponding videos. For example, in set-play analysis of an opponent, one can identify target zones and link them to the most dangerous players and their shooting or goal efficiency. In transition analysis, one can analyse the key players involved, as well as their most typical behaviour after winning or losing the ball.
About STATS
STATS is the global leader in sports intelligence. Trusted by the world’s most innovative teams, leagues and brands seeking the winning edge at the intersection of sports and technology, STATS combines the industry’s fastest and most accurate data platform with video analysis, sports content and research, player tracking through STATS SportVU®, and a range of customisable digital solutions for brands. The pioneer of live sports data, STATS continues to speed innovation in the industry today to enhance both team performance and fan experience. For more information, go to www.stats.com and follow STATS on Twitter @STATSInsightsUK .
View source version on businesswire.com: http://www.businesswire.com/news/home/20170725005426/en/
Contact:
STATS
Dennis Dougherty, 847-583-2680
ddougherty@stats.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
